Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Rapid Intermittent Compared With Slow Continuous Correction in Severe Hyponatremia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In emergency setting (2016.6-) and/or inpatients at ward (2018.9-)~* Glucose corrected serum sodium ≤125 mmol/L~* Patients with moderately severe or severe symptom~  * Moderately severe~    :Nausea without vomiting Drowsy, Headache General weakness, myalgia~ * Severe :Vomiting, Stupor, Seizures, Coma (Glasgow Coma Scale ≤8)~* written consent~Exclusion Criteria:~* Pseudohyponatremia: serum osmolality \> 275 mOsm/kg~  - If the serum osmolality is \> 275 mOsm/kg but the BUN is ≥ 30 mg/dL, the patients can be registered if calculated serum osmolality (2 x plasma \[Na\] + \[Glucose\]/18) is \<275 mOsm/kg~* Primary polydipsia: urine osmolality ≤ 100 mOsm/kg~* Glucose corrected serum sodium \>125 mmol/L~* Arterial hypotension (SBP \<90mmHg and MAP \<70mmHg)~* Anuria or urinary outlet obstruction~* Liver disease~  * transaminase levels \>3 times the upper limit normal~ * Known LC with ascites or diuretics use or PSE Hx or Varix Hx~* Uncontrolled diabetes mellitus (HbA1C \> 9%)~* Women who are pregnant or breast feeding~* History of cardiac surgery excluding PCA, acute myocardial infarction, sustained ventricular tachycardia, ventricular fibrillation, acute coronary syndrome, cebrovascular trauma, and increased intracranial pressure within the 3 months prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intermittent bolus group (Type: ACTIVE_COMPARATOR): \<\<Within 6hr\>\>~* Moderately Severe : 3% saline 2ml/kg over 20min \*1 (unknown bwt 100ml)~* Severe :3% saline 2ml/kg over 20min \*2 (unknown bwt 100ml)~\<additional treatment\> Repeat 3% saline 2ml/kg over 20min at every sample time point (at 1/6hr) till Na 5-9 mmol/L inc from initial Na and sx relief~\<\<During 6-24hr\>\>~- Moderately Severe or Severe~: Repeat 3% saline 2ml/kg over 20min at every sample time point(at 12/18/24hr) till Na 5-9 mmol/L inc from initial Na and sx relief~\<\<During 24-48hr\>\>~* Moderately Severe or Severe : Repeat 3% saline 2ml/kg over 20min at every sample time point (at 30/36/42/48hr) till Na 10-17 mmol/L inc from initial Na or Na ≥ 130mmol and sx relief
- slow continuous infusion group (Type: ACTIVE_COMPARATOR): \<\<Within 24hr\>\>~- Moderately Severe: 3% saline 0.5ml/kg/hr (unknown bwt 25ml/hr)~- Severe: 3% saline 1ml/kg/hr (unknown bwt 50ml/hr)~Infusion protocol modification as below by Na at every sample time point (at 1/6/12/18/24 hr)~If Na 5-9 mmol/L inc from initial Na and sx relief : stop 3% saline infusion regardless of △ Na~if △ Na inc \<0.5mmol/hr or △ Na inc \<3mmol/6hr : add 0.25ml/kg/hr, restart 0.5ml/kg/hr if previously stopped~if △ Na inc ≥0.5mmol/hr or △ Na inc ≥ 3mmol/6hr~: maintain infusion rate~\<\<During 24-48hr\>\>~- Moderately Severe and Severe~Infusion protocol modification as below by Na at every sample time point (at 30/36/42/48hr)~If Na 10-17 mmol/L inc from initial Na or Na ≥ 130mmol and sx relief~: stop 3% saline infusion regardless of △ Na~if △ Na inc \<1.5mmol/6hr~: add 0.25ml/kg/hr or restart 0.25ml/kg/hr if previously stopped~if △ Na inc ≥ 1.5mmol/6hr~: maintain infusion rate

Based on this trial design, predict the completion outcome and termination type (if applicable).